China Meheco Group (600056.SH): Betamethasone Hydrochloride Tablets and other medicines are expected to be selected for the national centralized procurement of drugs.

17:55 03/08/2026

China Pharmaceuticals (600056.SH) announced that on July 31, 2026, its subsidiary participated in the bidding for the twelfth batch of the national centralized drug procurement. According to the proposed selection results announced on-site by the National Organization for Drug Joint Procurement Office, the company's products, including Betahistine Hydrochloride Tablets, Vornesetrone Fumarate Tablets, Vitamin B6 Injection, Sacubitril and Valsartan Sodium Tablets, Injection Sulfate of Isavuconazole, Tobramycin Sulfate Edoxaban Tablets, Carbenicillin Injection, and Valaciclovir Hydrochloride Tablets, are proposed for selection in this centralized procurement.

China Meheco Group (600056.SH) announced that on July 31, 2026, its subsidiary participated in the bidding for the twelfth batch of national centralized procurement of pharmaceuticals. According to the proposed selection results announced on-site by the National Drug Centralized Procurement Office, the company's products, including Betahistine Dihydrochloride Tablets, Vornatacine Tablets, Vitamin B6 Injection, Sacubitril Valsartan Sodium Tablets, Injectable Isavuconazole Sulfate, Edoxaban Tosilate Tablets, Calcitriol Sodium Injection, and Valaciclovir Hydrochloride Tablets, are proposed for selection in this centralized procurement. This centralized procurement is the twelfth batch of nationally organized procurement of drugs, during which medical institutions will prioritize the use of the selected varieties from this centralized procurement and ensure the completion of the agreed procurement volume. If the company's aforementioned products are confirmed as winning bids, the subsequent signing of procurement contracts and implementation will benefit the expansion of sales scale for related products, increase market share, enhance the company's brand influence, and have a positive impact on the companys future operating performance.

Luxshare Precision Industry (02475): As of the end of July, a total of 17.665 million A-shares have been repurchased.

RAYMOND IND (00229) issues a profit warning, expecting a loss of approximately HKD 10 million to HKD 11 million for the interim period, transitioning from profit to loss compared to the same period last year.

LOGORY (02482) issued a profit warning, expecting a mid-term net loss of about 20.3 million yuan, a loss compared to a profit in the same period last year.

Luxshare Precision Industry (02475): As of the end of July, a total of 17.665 million A-shares have been repurchased.

LOGORY (02482) issued a profit warning, expecting a mid-term net loss of about 20.3 million yuan, a loss compared to a profit in the same period last year.